244 related articles for article (PubMed ID: 28150354)
1. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.
Han X; Zhou Y; You Y; Lu J; Wang L; Hou H; Li J; Chen W; Zhao L; Li X
Cell Biol Int; 2017 Apr; 41(4):405-414. PubMed ID: 28150354
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.
Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H
Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
4. A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells.
Han X; Zhen S; Ye Z; Lu J; Wang L; Li P; Li J; Zheng X; Li H; Chen W; Li X; Zhao L
Cell Physiol Biochem; 2017; 41(3):973-986. PubMed ID: 28222434
[TBL] [Abstract][Full Text] [Related]
5. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
6. The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance.
Manzoor HB; Asare-Werehene M; Pereira SD; Satyamoorthy K; Tsang BK
J Ovarian Res; 2024 Jan; 17(1):15. PubMed ID: 38216951
[TBL] [Abstract][Full Text] [Related]
7. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
8. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
9. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.
Duan H; Yan Z; Chen W; Wu Y; Han J; Guo H; Qiao J
Gynecol Oncol; 2017 Nov; 147(2):408-417. PubMed ID: 28851501
[TBL] [Abstract][Full Text] [Related]
10. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
11. Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin.
Zhou Z; Zhang HS; Liu Y; Zhang ZG; Du GY; Li H; Yu XY; Huang YH
J Cell Physiol; 2018 Feb; 233(2):1359-1369. PubMed ID: 28513825
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
14. TET3 inhibits TGF-β1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells.
Ye Z; Li J; Han X; Hou H; Chen H; Zheng X; Lu J; Wang L; Chen W; Li X; Zhao L
J Exp Clin Cancer Res; 2016 May; 35():72. PubMed ID: 27141829
[TBL] [Abstract][Full Text] [Related]
15. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
16. Triptolide antagonized the cisplatin resistance in human ovarian cancer cell line A2780/CP70 via hsa-mir-6751.
Wang R; Ma X; Su S; Liu Y
Future Med Chem; 2018 Aug; 10(16):1947-1955. PubMed ID: 29966441
[TBL] [Abstract][Full Text] [Related]
17. TET1 exerts its anti-tumor functions via demethylating DACT2 and SFRP2 to antagonize Wnt/β-catenin signaling pathway in nasopharyngeal carcinoma cells.
Fan J; Zhang Y; Mu J; He X; Shao B; Zhou D; Peng W; Tang J; Jiang Y; Ren G; Xiang T
Clin Epigenetics; 2018 Aug; 10(1):103. PubMed ID: 30075814
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
[TBL] [Abstract][Full Text] [Related]
20. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
